# Activity log — QE-NOB-1.0

This is an audit of user-facing scope decisions and concrete work. It is not a verbatim transcript and does not store private hidden reasoning.

## 2026-10-22 — fresh-start instruction
- User instructed: forget existing findings and start a new QuantEvolve study to find profitable strategies using naked option buying.
- Scope interpreted as NIFTY 50 long-premium options, constrained evolution and after-cost net profitability; no short-option legs.
- Existing performance reports are explicitly excluded from priors, strategy seeding, score computation and evidence. New run/cache/results identifiers are isolated.
- User previously said “No tester”; the fresh workflow therefore proceeds developer-led and does not rely on a tester branch/report.
- Phase 1 protocol created. No QE-NOB-1.0 market data has been acquired and no profitability claim is made.

## 2026-10-22 — developer-led workflow preference reaffirmed
- User explicitly reiterated: “No tester.” The QE-NOB-1.0 work will proceed without creating, invoking, or waiting on an independent tester branch/report.
- Quality controls remain automated developer-side gates: unit tests before/after the run, locked chronological OOS, family-wide multiple-testing correction, cost stress tests, and an explicit execution-data limitation. These are not described as independent testing.
- At the latest check, GitHub Actions run 39712854501 remained in progress at “Run fresh QuantEvolve study”; the run had not yet produced a report that supports profitability conclusions. No strategy is approved at this point.


## 2026-10-22 — tester explicitly declined
- User clarified: “No tester”. This fresh QE-NOB study will proceed developer-led; do not create, invoke, or wait for an independent tester branch/report.
- This changes the governance route only, not the statistical or data-quality gates. Developer-side validation and automated tests remain mandatory; limitations and unresolved execution-data gates must be disclosed.
- At this update, workflow #39712854501 was still running in the QuantEvolve study step. No strategy result is inferred from an in-progress run.
